Kisqali(ribociclib)

[Function and indication] On March 13, 2017, the U.S. FDA approved KISQALI as a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

[Model and specification] Tablet: 200 mg

[Usage and dosage] Recommended starting dose: 600 mg orally (three 200 mg tablets) taken once a day with or without food for 21 consecutive days followed by 7 days without treatment.

[Adverse reactions] The most common adverse reactions (incidence ≥ 20%) are neutropenia, nausea, fatigue, diarrhea, leukopenia, alopecia, vomiting, constipation, headache and back pain.

[Manufacturer] Novartis